Literature DB >> 16723087

Down-regulation of p210(bcr/abl) by curcumin involves disrupting molecular chaperone functions of Hsp90.

Li-Xian Wu1, Jian-Hua Xu, Xiu-Wang Huang, Kun-Zhong Zhang, Cai-Xia Wen, Yuan-Zhong Chen.   

Abstract

AIM: To investigate the effects of curcumin (Cur) on p210(bcr/abl) level in K562 cells, and the relationship between these effects and the molecular chaperone functions of heat shock protein 90 (Hsp90).
METHODS: Flow cytometry and Western blot were used to examine the abundance of p210(bcr/abl), Hsp90, p23, Hsp70, and p60(Hop) in K562 cells treated with Cur. Reverse transcription polymerase chain reaction (RT-PCR) was used to determine the bcr-abl mRNA level in K562 cells treated with Cur. After co-immunoprecipitation of p210(bcr/abl) and its molecular chaperones, the immunoprecipitate was then subjected to Western blot analysis with anti-Hsp90, anti-Hsp70, anti-p23, and anti- p60(Hop)mAb.
RESULTS: An exposure of K562 cells to Cur produced time-dependent down-regulation of p210(bcr/abl), the inhibition rate of p210(bcr/abl) in K562 cells determined by flow cytometry after treatment with Cur 27.2 micromol/L for 1 h, 6 h, 12 h and 24 h was 31.2%, 63.7%, 81.3% and 94.5%, respectively. In contrast, Cur had almost no influence on bcr-abl mRNA level. Treatment with Cur for 24 h reduced the association of p210(bcr/abl) with Hsp90/p23 complex, while increasing the association of p210(bcr/abl) with Hsp70/ p60(Hop) complex; however, the total protein abundance of Hsp90, p23, and p60(Hop) in K562 cells had no apparent change, while Hsp70 increased greatly.
CONCLUSION: Down-regulation of p210(bcr/abl) by Cur involves dissociating the binding of p210(bcr/abl) with Hsp90/p23 complex. In contrast, the association of p210(bcr/abl) with Hsp70/ p60(Hop) complex increased.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723087     DOI: 10.1111/j.1745-7254.2006.00326.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  8 in total

Review 1.  Cancer cell signaling pathways targeted by spice-derived nutraceuticals.

Authors:  Bokyung Sung; Sahdeo Prasad; Vivek R Yadav; Bharat B Aggarwal
Journal:  Nutr Cancer       Date:  2011-12-09       Impact factor: 2.900

2.  C1206, a novel curcumin derivative, potently inhibits Hsp90 and human chronic myeloid leukemia cells in vitro.

Authors:  Ying-Juan Fan; Yi-Xiang Zhou; Lian-Ru Zhang; Qiao-Fa Lin; Ping-Zhang Gao; Fang Cai; Li-Ping Zhu; Bi Liu; Jian-Hua Xu
Journal:  Acta Pharmacol Sin       Date:  2017-12-07       Impact factor: 6.150

3.  The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition.

Authors:  Chiara Giommarelli; Valentina Zuco; Enrica Favini; Claudio Pisano; Fabrizio Dal Piaz; Nunziatina De Tommasi; Franco Zunino
Journal:  Cell Mol Life Sci       Date:  2009-12-29       Impact factor: 9.261

4.  C0818, a novel curcumin derivative, induces ROS-dependent cytotoxicity in human hepatocellular carcinoma cells in vitro via disruption of Hsp90 function.

Authors:  Ahmed Attia Ahmed Abdelmoaty; Ping Zhang; Wen Lin; Ying-Juan Fan; Sheng-Nan Ye; Jian-Hua Xu
Journal:  Acta Pharmacol Sin       Date:  2021-04-06       Impact factor: 6.150

5.  C0818, a novel curcumin derivative, interacts with Hsp90 and inhibits Hsp90 ATPase activity.

Authors:  Yingjuan Fan; Yang Liu; Lianru Zhang; Fang Cai; Liping Zhu; Jianhua Xu
Journal:  Acta Pharm Sin B       Date:  2016-06-18       Impact factor: 11.413

6.  FM807, a curcumin analogue, shows potent antitumor effects in nasopharyngeal carcinoma cells by heat shock protein 90 inhibition.

Authors:  Min Ye; Wei Huang; Wen-Wei Wu; Yang Liu; Sheng-Nan Ye; Jian-Hua Xu
Journal:  Oncotarget       Date:  2017-02-28

Review 7.  The Role of Sulfhydryl Reactivity of Small Molecules for the Activation of the KEAP1/NRF2 Pathway and the Heat Shock Response.

Authors:  Albena T Dinkova-Kostova
Journal:  Scientifica (Cairo)       Date:  2012-12-23

8.  Curcumin targets multiple enzymes involved in the ROS metabolic pathway to suppress tumor cell growth.

Authors:  Yonika Arum Larasati; Noriko Yoneda-Kato; Ikuko Nakamae; Takashi Yokoyama; Edy Meiyanto; Jun-Ya Kato
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.